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Background. Random whole body vibration (WBV) training leads to beneficial short-term effects in patients with Parkinson’s
disease (PD). However, the effect ofWBV lasting several weeks is not clear.Objectives. The aim of this study was to assess a random
WBV training over 5 weeks in PD.Methods. Twenty-one participants with PDwere allocated to either an experimental or a placebo
group matched by age, gender, and Hoehn&Yahr stage. The WBV training consisted of 5 series, 60 s each. In the placebo group,
vibration was simulated.The primary outcome was the change of performance in Functional reach test (FRT), step-walk-turn task,
biomechanical Gait Analysis, Timed up and go test (TUG), and one leg stance. Findings. In most of the parameters, there was no
significant interaction of “time∗group.” Both groups improved significantly in Gait parameters, TUG, and one leg stance. Only in
the FRT [𝐹(1, 15) = 8.397; 𝑃 < 0.05] and in the TUG [𝐹(1, 15) = 4.971; 𝑃 < 0.05] the experimental group performed significantly
better than the placebo group.Conclusions. RandomWBV training over 5 weeks seems to be less effective than reported in previous
studies performing short-term training. The slight improvements in the FRT and TUG are not clinically relevant.
1. Introduction
One of the cardinal symptoms of Parkinson’s disease (PD) is
postural instability which a lot of patients suffer from. While
drugs can improve the other cardinal symptoms (bradyki-
nesia, tremor, and rigor), drugs show no effect or even a
detrimental effect on postural instability [1–4]. Therefore, it
is essential to consider other treatment methods. Balance
training and whole body vibration (WBV) training are two
possibilities to counteract postural instability. However, the
underlying mechanisms of WBV are not clearly understood
and clinical efficacy ofWBV in neuromuscular diseases is not
proven [5, 6]. Previous studies of the effect on WBV training
have shown inconsistent results [7–15].
On the one hand, results have shown that, directly after a
randomWBV intervention, the symptoms rigor, tremor, and
postural stability have been improved in patients with PD [8–
10]. RandomWBV seems to improve tactile sensitivity better
than steady vibrations [11]. Deficits in proprioceptive pro-
cesses have been reported in PD [12]; therefore, these patients
could especially benefit from randomWBV. Furthermore, in
other neurological diseases like multiple sklerosis, positive
effects could be shown with WBV [13].
On the other hand, there was no superior efficiacy of
WBV training lasting several weeks in comparison to conven-
tional balance training [14]. In this study with PD patients,
steady WBV was used. Also, Arias et al. [15] showed that
steady WBV and a placebo treatment lasting several weeks
caused the same positive effects in PD patients. Both groups
performed their training in 12 sessions on nonconsecutive
days over 5 weeks. However, in this study, random vibration
was not used.
So far, either immediate effects of randomWBV or train-
ing with steady WBV lasting several weeks has been evalu-
ated, but not whether there are higher effects of a random
WBV training lasting several weeks in comparison to a
placebo treatment. Quantitative differences in the perfor-
mance of tasks with potential fall risk [16, 17] (bending for-
ward, climbing steps) have been shown between participants
with PD and healthy controls [18]. Therefore, in this study,
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Figure 1: Flow diagram.
the same tasks were assessed to investigate the effect of ran-
dom WBV in PD during performing these tasks. The aim of
this study was to evaluate a training of randomWBV lasting
5 weeks with quantitatively measured tasks in comparison
to a placebo group to whom the vibration was only simu-
lated. Additionally intrasession effects were assessed with the
“Timed up and go test” (TUG) and a “one leg stance test.”
2. Methods
2.1. Participants. In total, 43 participants diagnosed with idi-
opathic Parkinson’s disease (Hoehn and Yahr stage 2-3)
were recruited in the outpatient clinic of the Department
of Neurology at the University of Regensburg as well as by
office-based board certified neurologists in Regensburg. The
participants were recruited between July and September
2011, and the trial was performed between October and
December 2011. Ten subjects were excluded due to advanced
osteoporosis, joint prosthesis, recent lumbar disc hernitation,
strong heart beat disturbances, or cancer. Another 12 subjects
with PD declined to participate. The remaining 21 partici-
pants with PD were matched by age, gender, and the Hoehn
and Yahr stage. Afterwards, the pairs were allocated in the
experimental group (𝑛 = 11) and in the placebo group
(𝑛 = 10). In each group, 1 participant declined to continue
after pretest and 2 participants of the experimental group
did not complete the study due to private reasons (Figure 1).
In the remaining subjects of the experimental group (𝑛 = 8)
and of the placebo group (𝑛 = 9), there were no significant
differences concerning age, height, weight, arm length, leg
length, disease duration, or daily equivalent dose of L-dopa
(Table 1). Furthermore, dementia could be excluded in all
participants (MMSE ≥ 24). All experimental trials as well
as the training sessions were performed in the ON-period
one hour after medication intake. There was no change
of dopaminergic medication during the trial period. The
execution of this study was approved by the local ethics
committee. All participants gave written informed consent
according to the Declaration of Helsinki.
2.2. Material. For the assessment of “Gait,” the “Functional
Reach Test” (FRT) and the “step-walk-turn task” (see below)
kinematics were measured using a six infrared camera
motion analysis system (VICON, Oxford Metrics, 200Hz)
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Figure 2: (a) Visualization of the Functional Reach Test (FRT) and calculation of the Center of Pressure (CoP) to the normalized foot length
in %. The horizontal distance between heel marker and toe marker was defined as 100%. (b) Test set-up for the intervention. Both groups
stood on the vibration platform with knees slightly bend. The placebo group had additionally to concentrate on the light on the wall.
and 16mm passive reflective markers. All markers were
placed according to the Plug-in gait full body-model. Ground
reaction forces were collected from a three-dimensional force
plate (AMTI, OR6-2000, 1000Hz) and the center of pressure
(CoP) was calculated. The CoP was normalized to each
participant’s foot length. We defined the distance between
heel marker and toe marker as 100%. The CoP position con-
cerning each subject’s foot length was measured in “standing
still” and for the displacement of the CoP during “bending
forward” in the FRT. For visualization see Figure 2(a).
2.3. Procedure and Measurements. Seven days before the first
and after the last training session, tasks of potential fall risk
(Gait, Functional reach and Step up and down, as well as
turning—evaluated in [18]) were quantitatively assessed and
the data of the UPDRS motor score were collected.
2.3.1. Biomechanical Gait Analysis. Instrumented 3D gait
analysis was used to quantitatively measure gait parameters
(velocity, step length, cadence, double support, and single
support) and to describe gait impairments in PD [19]. Partici-
pants with PDwalked in the laboratory with their self-chosen
velocity on a 9m walkway while kinematic and kinetic data
weremeasured. After habituation, 10 trials were recorded. For
data analysis three trials for each leg (strike on the force plate)
were taken into account. The mean spatiotemporal parame-
ters and the mean ground reaction forces were analyzed.
2.3.2. Functional Reach Test (FRT). This common test de-
scribed by Duncan et al. [20] was slightly modified to
reflect activities of daily living measured by motion capture.
Participants tried to reach forward as far as possible and
grasped a pen with one hand from a table without lifting
their heels (table height 0.80m, distance toe to table 0.30m).
Some pens were distributed across the complete length of the
table with an inter-pen-distance of 0.05m. Each participant
performed this task three times with the preferred arm.Mean
values of the maximum reach distance and the displacement
of the CoP were used for analysis.
2.3.3. Step-Walk-Turn Task. This task was evaluated before
and distinguishes patients with PD and healthy controls [18].
Participants must step up onto a 0.25m high box, walk 2m
to the end of the box, turn 180 degrees, walk back, and step
down. The step before stepping up and the step used to get
down were placed on a force plate. Ground reaction forces,
the resulting velocity of the trunk in stepping down, steps
for turning, and the time needed to accomplish the task were
measured. The participants performed this task three times
and mean values were used for analysis.
2.3.4. UPDRS Motor Score. The UPDRS motor score was as-
sessed by board-certified neurologists who also did a classifi-
cation of the Hoehn and Yahr stage [21, 22].
Furthermore, acute effects of the intervention were eval-
uated using the “Timed up and go” test (TUG) and a “one leg
stance test,” both explained below. At pretest and posttest as
well as on the 3rd, 5th, 7th, 9th, and 11th training sessions,
participants had to perform these two tasks (5 intrasession
tests).
2.3.5. TUG. Participants sit on a chair, stand up, walk 3m,
turn, walk back to the chair, and sit down [23]. The time to
accomplish the task was recorded with a stopwatch.
2.3.6. One Leg Stance Test. Due to reasons of optimal clinical
balance assessment, the one leg stance test was performed in
addition to the gait and pull test items of the UPDRS [24].
Participants stand unsupported on the preferred leg as long
as they can (maximum60 s).The time inwhich one leg stance
could be performed was recorded with a stopwatch.
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2.4. Intervention. In the same five-week time period, both
groups received an intervention of 12 sessions on nonconsec-
utive days, two to three times a week.The experimental group
exercised on the vibration platform SRT Zeptor Medical
plus noise. In order to make an accurate comparison to
previous studies [8, 9, 15], 5 sets of stimulation lasting 60 s
with a frequency of 6Hz (±1 Hz noise, 3mm vibration ampli-
tude) were performed by the experimental group. The break
between the sets was set to 60 s. During the intervention, the
participants were instructed to stand on the platform in a
double supported stable stance with their knees slightly bent.
The placebo group, being not aware of the common
vibration stimulus (single-blinded), stood on the vibration
platform in the same basic position as the experimental
group. The participants of the placebo group were instructed
to stand as still as possible during the intervention with the
target of keeping body sway to a minimum. In the placebo
group the vibration was just simulated by an audible and
noticeable signal. A small vibration device was put on the
body of the vibration platform and could be switched on or off
by a remote control.The vibration feels as if someone is using
a percussion drill against the floor next door. However, the
vibration of the small device was not transferred to the vibra-
tion platform. In contrast to the experimental group, partici-
pants of the placebo group had to additionally draw attention
to a visual signal fixed on the wall. As long as participants
stood still the light was green.When their body began to sway
the examiner used another remote control to switch the green
light to red which signaled the participants to concentrate on
standing still (Figure 2(b)). The participants thought that the
visual feedback was connected to the vibration platform.
2.5. Statistical Analysis. All statistical analyses were per-
formed using PASW Statistics for Windows, Version 18.0.0.
Anthropometric differences between groups were tested by
the 𝑡-test for independent samples. The significance level
was set at 𝑃 < 0.05. To calculate the effects of the
intervention a 2 × 2 ANOVA with repeated measures was
used with “group” (experimental-placebo) as the between
subject factor and “time” (pre-post) as the within subject
factor. To investigate possible short term effects, an ANOVA
with repeatedmeasures was conducted and “group”was set as
the between subject factor. The within subject factor “time”
was defined with 7 levels (pretest, Session 3, 5, 7, 9, and 11,
and posttest).The difference between the current test and the
previous test was statistically assessed. For post hoc tests, a
Bonferroni alpha-correction was performed.
3. Results
There was a significant main effect of factor “time” (pre-post)
in some variables. All gait parameters changed significantly
in both groups from pretest to posttest: velocity (𝐹(1, 15) =
28.785;𝑃 = 0.000; 𝜂2 = 0.657 [𝜂2 = partial eta-quadrat]), step
length (𝐹(1, 15) = 5.740; 𝑃 = 0.030; 𝜂2 = 0.277), and cadence
increased (𝐹(1, 15) = 32.234; 𝑃 = 0.000; 𝜂2 = 0.682), double
support (𝐹(1, 15) = 33.037; 𝑃 = 0.000; 𝜂2 = 0.688) and single
support decreased (𝐹(1, 15) = 18.870;𝑃 = 0.000; 𝜂2 = 0.557).
In the step-walk-turn task a significant main effect of factor
“time” was seen in steps for turning (𝐹(1, 15) = 5.310; 𝑃 =
0.036; 𝜂2 = 0.261) and in the time to accomplish the task
(𝐹(1, 15) = 18.441;𝑃 = 0.001; 𝜂2 = 0.551). A significantmain
effect of factor “time” was also seen in the TUG (𝐹(1, 15) =
12.422; 𝑃 = 0.003; 𝜂2 = 0.453) and the one leg stance test
(𝐹(1, 15) = 7.779; 𝑃 = 0.014; 𝜂2 = 0.341).
There were no significant main effects of the factor
“group” in any of the measured parameters.
Themain outcome of this study is the interaction between
“time” (pre-post) and “group” (experimental-placebo). Only
in a few variables a significant interaction could be found:
reach distance in the FRT (𝐹(1, 15) = 11.878; 𝑃 = 0.004;
𝜂
2
= 0.359), TUG (𝐹(1, 15) = 4.971; 𝑃 = 0.041; 𝜂2 = 0.249),
and UPDRS Item “Rigidity” (𝐹(1, 15) = 6.281; 𝑃 = 0.024;
𝜂
2
= 0.295). In the FRT and TUG the experimental group
performed better in the posttest whereas in the “Rigidity”
Item the placebo group improved lightly from pretest to
posttest. All other variables showed no significant interaction
of “time∗group” (Table 2).
3.1. Intrasession Evaluation. The intrasession evaluation of
the TUG showed a significant main effect of the factor “time”
at the 5th, 7th, 9th, and 11th sessions and posttest, respectively,
in comparison to the previous session (all 𝑃 values < 0.05).
There were significant interactions of “time∗group” between
the 5th and 3rd sessions (𝐹(1, 15) = 8.371; 𝑃 = 0.011; 𝜂2 =
0.358). The experimental group [mean (SD): 5th session: 9,8
(2,4) s; 3rd session: 11,0 (2,4) s] improved significantly but the
placebo group [5th session: 11,1 (2,2) s; 3rd session: 10,8 (2,8) s]
did not change TUG performance. Between the 11th and 9th
session there was a significant interaction (𝐹(1, 15) = 5.461;
𝑃 = 0.034; 𝜂2 = 0.267) but single comparison did not reach
significance.There was no significantmain effect of the factor
“group” (𝐹(1, 15) = 0.282; 𝑃 = 0.603).
For the “one leg stance,” there was a significant main
effect of the factor “time” between the 3rd session and pretest
(𝐹(1, 15) = 4.888; 𝑃 = 0.043; 𝜂2 = 0.246) (Figure 3). Between
all other test sessions, there were no significantmain effects of
the factor “time.” There were also no significant interactions
of “time∗group” between the different test sessions and the
main effect of the factor “group” was not significant.
4. Discussion
The aim of this study was to evaluate an intervention using
random WBV lasting 5 weeks with quantitatively measured
tasks in comparison to a placebo group.
In most of the parameters a significant interaction of the
main outcome measure “time∗group” could not be estab-
lished. Significant differences could just be found in the
reach distance, TUG, and “Rigidity” Item of the UPDRS. All
other measured parameters improved in both groups or did
not change significantly from pretest to posttest. In contrast
to other studies [14, 15], we used random WBV but the
effect of the experimental group was similar to the placebo
group. Analogical results have been shown in a previous
study which used a steady vibration stimulus and equivalent
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Figure 3: Results of the intrasession evaluation in the “Timed up and go test” (TUG (a)) and the “one leg stance test” (b). TUG: significant
interaction “time∗group”; one leg stance: significant main effect of factor “time” (∗𝑃 < 0.05).
training conditions as in this investigation [15].Therefore, we
hypothesize that random WBV will not lead to more benefit
than a steady WBV when training consists of 12 sessions
in a period of 5 weeks with the training conditions used in
previous studies [8, 9, 15].
In the past, Griffin [25] has shown that organisms have
a high sensitivity to vibration at 4–8Hz whereas vibration
frequencies above 10Hz are less important. The frequency
of 6Hz fits within the suggested range but it is possible that
other frequencies in the range of 4–8Hz are more effective.
In this context, a recent study including subjects with PD
showed no significant short time effects of WBV between
the frequencies 3Hz, 6Hz, and 9Hz and in comparison
to a placebo group [26]. These results support the demand
for further investigation of different vibration frequencies.
Additionally, the necessary number ofWBV training sessions
should be examined in the future because subjects with PD
who participated in our study reported that themain training
effects only lasted for several hours. This statement confirms
the results of a recent reviewwhich concludes thatWBV leads
to short term improvements in PD whereas longer duration
of WBV has no greater beneficial effect in comparison to
physical therapy [27].
As King et al. [10] established, there was an increase
in step length as well as a decrease in rigidity and tremor
when treated by short-termWBV in comparison to a control
group which did not get additional treatment. In this study,
the placebo group also improved in some parameters from
pretest to posttest and performed better than the experimen-
tal group, especially in the “Rigidity” Item of the UPDRS
Motor Score. The impact of the placebo treatment could
explain the improvement of rigidity in the placebo group,
because in previous studies it has been shown that the placebo
effect wields more influence on bradykinesia and rigor than
on tremor, gait, and balance [28]. However, the placebo group
also improved in gait; therefore, other explanations have
to be taken into account. In previous studies, it has been
shown that acoustic signals can improve motor symptoms
in participants with PD like arm and finger movements [29]
or gait parameters [30, 31]. Also visual feedback has been
shown to improve balance [32] and gait [33] in PD.Therefore,
it is conceivable that the positive effects in gait parameters
arose from acoustic signals or visual feedback, both used in
the placebo treatment. Moreover, the frequent testing of the
TUG and the “one leg stance” during the training period
could have had an effect on gait and as well as on turning.
We assume that the placebo group could have been improved
in some parameters due to different reasons. However, we
have shown that random WBV training in the training
conditions we employed is not more effective than a placebo
treatment, which additionally included acoustic signals and
visual feedback.
Although there was a significant interaction of “time∗
group” in the reach distance of the FRT and TUG, prepost
differences were not huge between groups. The effect sizes
of both parameters were weak, suggesting that randomWBV
has caused differences of scientific relevance than of clinical
relevance in this study. Interestingly, both groups improved
their performance in the one leg stance by about 10 s (30%)
over fiveweeks.This improvement probably could bemore an
effect of frequent task repetition and habituation than of the
WBV or placebo intervention. That means also the changes
in the FRT and TUG could be established due to motor
task learning while performing repeated measures. Taken
8 Parkinson’s Disease
together, it is unlikely that the random WBV intervention is
responsible for functional improvements in PD after a 5 week
training period.
5. Limitations
The results of this study are limited by the sample size. Fur-
thermore, subjects with different forms (acinetic-rigid,
tremor dominant) of PD participated and both the training
sessions and the tests were performed in the ON period.
6. Conclusion
In this study, we showed that an intervention with random
WBV could lead to effects similar to a placebo treatment.
Regarding a training over 5 weeks, the random WBV stim-
ulus seems to be less effective than expected in studies
which investigated short-term effects. The stimulus type
(random/steady) requires further investigation in the future,
in addition to the vibration frequency, training position, and
the number of the vibration sessions.
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